

PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

[View Online](#)

1.

Smith, K. S. & Rudolph, U. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. *Neuropharmacology* **62**, 54-62 (2012).

2.

Luscher, B., Shen, Q. & Sahir, N. The GABAergic deficit hypothesis of major depressive disorder. *Molecular Psychiatry* **16**, 383-406 (2011).

3.

Balon, R. Mood, anxiety, and physical illness: body and mind, or mind and body? *Depression and Anxiety* **23**, 377-387 (2006).

4.

Kalueff, A. V. & Nutt, D. J. Role of GABA in anxiety and depression. *Depression and Anxiety* **24**, 495-517 (2007).

5.

Cryan, J. F. & Kaupmann, K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. *Trends in Pharmacological Sciences* **26**, 36-43 (2005).

6.

Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. *Trends in Pharmacological Sciences* **24**, 580–588 (2003).

7.

Levine, J., Cole, D. P., Chengappa, K. N. R. & M.D., S. G. Anxiety disorders and major depression, together or apart. *Depression and Anxiety* **14**, 94–104 (2001).

8.

Freund, T. F. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. *Trends in Neurosciences* **26**, 489–495 (2003).

9.

Strange, P. G. *Brain biochemistry and brain disorders*. (Oxford University Press, 1992).

10.

Carvalho, A. F. & Van Bockstaele, E. J. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **38**, 59–67 (2012).

11.

Atwood, B. K., Straiker, A. & Mackie, K. CB2: Therapeutic target-in-waiting. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **38**, 16–20 (2012).

12.

Hill, A. J., Williams, C. M., Whalley, B. J. & Stephens, G. J. Phytocannabinoids as novel therapeutic agents in CNS disorders. *Pharmacology & Therapeutics* **133**, 79–97 (2012).

13.

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy.

https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.

14.

H. Attarian, O. A. Treatment of disorders of hypersomnolence. **16**, 302–302.

15.

N.P. Robertson, K. J. P. Narcolepsy: environment, genes and treatment. **261**, 1644–1646 (2014).

16.

Cera, N., Tartaro, A. & Sensi, S. L. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE **9**, (2014).

17.

Saper, C. B. & Scammell, T. E. Emerging therapeutics in sleep. Annals of Neurology **74**, 435–440 (2013).

18.

Eric J. Olson, K. R. Management of common sleep disorders. **88**, 231–238 (2013).

19.

Hoyer, D. & Jacobson, L. H. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides **47**, 477–488 (2013).

20.

Carlos H. Schenck, M. W. M. Insights from studying human sleep disorders. **437**, 1279–1285 (2005).

21.

Stores, G. Medication for sleep-wake disorders. Archives of Disease in Childhood **88**, 899–903 (2003).

22.

Kilduff, T. S. & Peyron, C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends in Neurosciences **23**, 359–365 (2000).

23.

Brisbare-Roch, C. Promotion of sleep by targeting the orexin system in rats, dogs and humans. **13**, 150–155 (2007).

24.

Mark W. Mahowald MD. Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports **7**, 167–172 (2007).

25.

Mahowald, M. W. & Schenck, C. H. Dissociated states of wakefulness and sleep. Neurology **42 Suppl. 6**, 44–52 (1992).